AGC Biologics plots roughly 100 layoffs as CDMO industry’s post-COVID hangover persists
By Fraiser Kansteiner
The CDMO has reached an inflection point where it needs to adjust business priorities and “right size and rebalance the resources of our organization,” a spokesperson said. (AGC Biologics)